Hypertension

Columbus, OH

40 Hypertension Trials near Columbus, OH

Power is an online platform that helps thousands of Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
No demographic group is more at risk for the double jeopardy of caregiving stress and hypertension (HTN) than African American women caring for a family member with Alzheimer's disease and related dementias (ADRD). Both situations lead to reduced quality of life and cardiovascular disease-a complication of uncontrolled hypertension. Maintaining the health of these caregivers is critical to support the well-being of the care recipients. Although some multi-component interventions have addressed ADRD caregiver's stress and quality of life, gaps remain in targeting interventions to address the complexity of chronic caregiving stress and hypertension self-care in African American women. This pilot study builds on the investigator's earlier work which showed that stress, blood pressure knowledge, and complex diet information deficits all interfered with older African American women's hypertension self-care. Lifestyle changes (stress management, reducing sodium, eating fruits/vegetables, and physical activity) are effective in managing hypertension. The investigator's Stage I pilot study is based on the scientific rationale that these lifestyle changes can be promoted by addressing stress reactivity/stress resilience, the psychological and physiological response of the body to stress, as the underlying mechanism to facilitate behavioral change. In this way the study can improve health outcomes (caregiver stress, quality of life, cardiovascular disease risk).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40+
Sex:Female

28 Participants Needed

Covid-19 is an additional stressor Black women have to deal with that may interfere with hypertension self-care management. Social connectedness is a source of resilience for Black women to promote mental and physical health. Unfortunately, in the face of the Covid-19 pandemic, social distancing is a challenge further isolating Black women from their networks. How is social connectedness to manage stress and emotional well-being in a social-distancing society for Black women with hypertension? The research team proposed a synchronous web-based version of Enhanced Co-Created Health Education InterventioN (eCo-CHIN) that build the success and best practices derived from the original intervention. A Covid-19 session will be included as a way of helping Black women to maintain resilience and self-care during stressful times. The eCo-CHIN intervention is innovative and timely because the research team are using a synchronous platform preparing Black women on how to deal with Covid-19 while taking care of self. The primary investigator for this pilot study (Dr. Wright) is a Black Early Stage Investigator and former KL2 (career development) awardee. The interdisciplinary research team has the expertise and resources to deliver this Enhanced Co-CHIN intervention.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:40 - 65
Sex:Female

30 Participants Needed

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 6-weeks (approximately), where reassessment of GFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2455 Participants Needed

This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79

14012 Participants Needed

The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition (valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the pancreas over 26 weeks assessed with glucose clamp studies among African Americans (AAs) with impaired glucose tolerance. The investigators hypothesize that combined RAAS/neprilysin inhibition will lead to greater improvement in insulin release from the pancreas and improved blood sugar compared to RAAS inhibition alone among AAs with impaired glucose tolerance.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18 - 65

90 Participants Needed

This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

357 Participants Needed

This trial tests lorundrostat, a drug that lowers blood pressure by blocking a hormone that makes the body hold onto salt and water. It targets patients whose high blood pressure isn't controlled by standard treatments.

Trial Details

Trial Status:Active Not Recruiting

285 Participants Needed

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

This is a pragmatic randomized control trial to evaluate the BETTER intervention compared to standard obstetrical care (control) to determine whether it helps to reduce maternal anemia and other adverse pregnancy outcomes. The BETTER intervention includes one motivational interviewing session and bi-weekly text messages to encourage patients to connect with resources that address their social needs, including housing, food, and transportation. Quantitative data will be used to study participant outcomes, including surveys, and electronic health record data.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female

550 Participants Needed

The purpose of this study is to determine if a low glycemic diet and lower-body electrical stimulation can reduce postprandial hypotension in individuals with chronic spinal cord injury.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

13 Participants Needed

Why Other Patients Applied

"I've been diagnosed with type 2 diabetes since 2000. I was on the highest dose of metformin, which didn't work for me. In 2022, I tried Ozempic, which had bad side effects. I'm not currently on anything to treat my diabetes, given my experiences (as well as some insurance denials). I'm glad that clinical trials exist to help me try to access the latest research. I'm frustrated but also motivated."

PL
Diabetes PatientAge: 53

"I have a known blockage developing in lower left main 50%, which my doctors are watching. We've considered surgery, but I'd like to rule out all possible other options first. I've done some research, which brought me to clinical trials."

PA
Artery Disease PatientAge: 64

"I have gasteroparesis which causes me extreme bloating, pain, acid reflux, occasional vomiting, nausea, and constipation. Most standard medications have not helped. I did some research to learn about investigational drugs, which I'd be excited to get to access through a trial."

BW
Gasteroparesis PatientAge: 38

"In December 2023 I had a stent placed in an artery. I was so glad that the blockage was found before I had either a heart attack, stroke, or both. I have been on Pravastatin for as long as I can remember but I continue to have elevated cholesterol levels. I'm trying to get ahead of my condition by learning more about the latest research and drugs available."

AQ
Hypercholesterolemia PatientAge: 57

"My ejection fraction is now 20-25%, quite low. Trying to optimize my medications at this time. I have had Biventricular pacemaker/ICD since 2007. I am doing everything I can to improve my health. Following a diet, exercising 30 minutes every day. Most days my systolic blood pressure is < 100. I had a L/R Cath in December and do not have any problems with my coronary arteries. I'm hoping to learn more about the latest research and drugs by participating in a trial. "

WB
Heart Failure PatientAge: 66

Know someone looking for new options? Spread the word